Before today’s trial readout no one was sure how remote ischaemic conditioning worked; now the investigators are pretty certain that it doesn’t.
With a narrow primary endpoint miss and a 15% decrease in hospitalisations, Novartis is adamant that Entresto can get approved in HFpEF.
Amgen's aggressive legal pursuit of Sanofi and Regeneron's Praluent might work, but will the PCSK9 developers ever recoup their costs?
Astrazeneca gets a win for its SGLT2 in heart failure irrespective of diabetes status, but Lilly and Boehringer’s Jardiance isn’t far behind.
Novartis has been reduced to a Paragon data dredge, but results with The Medicines Company’s inclisiran, Astrazeneca’s Brilinta and Cellaegis’ AutoRIC device should pique…
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
Alcohol kills – and in this case, that could be a good thing.
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.